Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.77 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.71 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.71 |
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11358119 | 0.90 | DNMT3A (0.72) | DNMT3AHDAC1HDAC6NLRP3 | |
| SCHEMBL8261934 | 0.88 | DNMT3A (0.84) | DNMT3AHDAC1HDAC6NLRP3 | |
| SCHEMBL1154596 | 0.87 | DNMT3A (0.68) | DNMT3AHDAC1HDAC6NLRP3 | |
| SCHEMBL11358623 | 0.87 | DNMT3A (0.82) | DNMT3AHDAC1HDAC6NLRP3 | |
| SCHEMBL4654636 | 0.87 | DNMT3A (0.82) | DNMT3AHDAC1HDAC6NLRP3 | |
| SCHEMBL1144242 | 0.87 | DNMT3A (1.00) | DNMT3AHDAC1HDAC6NLRP3 | |
| SCHEMBL18029599 | 0.87 | DNMT3A (0.82) | DNMT3AHDAC1HDAC6NLRP3 | |
| SCHEMBL29808416 | 0.87 | DNMT3A (1.00) | DNMT3AHDAC1HDAC6NLRP3 | |
| SCHEMBL11365033 | 0.86 | DNMT3A (0.67) | DNMT3AHDAC1HDAC6NLRP3 | |
| SCHEMBL21586535 | 0.86 | DNMT3A (0.80) | DNMT3AHDAC1HDAC6NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11130731-B2 | Sulfonylureas and related compounds and use of same | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) | 2021-09-28 | — | — | US | disclosed |
| US-20190119241-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11130731-B2 | Sulfonylureas and related compounds and use of same | NLRP3, PYCARD, IAPP | DNMT3A 4361/4885HDAC1 2157/4885HDAC6 1704/4885 |
| US-20190119241-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | DNMT3A 4640/4885HDAC1 421/4885HDAC6 602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.